$23.35+60.15% · 3M
Moving avg
1W+6.86%
1M+34.12%
3M+60.15%
6M+62.72%
YTD+104.47%
1Y+184.76%
3Y+11.30%
5Y+29.22%
52-week range
$7.48100% of range$19.60
Company health
Value0/6
Growth3/6
Profitability0/6
Health5/6
Dividend0/6
Bull vs bear
Strengths
- Analysts see 40% upside to a $33 target
- Analyst consensus is "Buy"
- Revenue compounding 180% a year
- Net cash on the balance sheet
Risks
- Burning free cash flow
Key statistics
Valuation
Market cap
$2.60B
Enterprise value
$1.94B
P/E ratio (TTM)
-13.17x
P/S ratio (TTM)
0.00x
EV/EBITDA
-13.16x
Per share & returns
EPS (TTM)
-$1.36
Dividend yield
0.00%
Beta (1Y)
-0.20
30-day change
+34.12%
Trading
Volume (24h)
1.43M
Previous close
$23.63
Shares outstanding
111.19M
About Amylyx Pharmaceuticals, Inc.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
AMLX
Amylyx Pharmaceuticals, Inc. is a mid-cap healthcare company in the Biotechnology industry. Its shares are listed on NASDAQ (United States) and trade under the ticker AMLX.
Frequently asked questions
What is Amylyx Pharmaceuticals, Inc.'s market cap?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market capitalization of $2.60B.
What sector is Amylyx Pharmaceuticals, Inc. in?
Amylyx Pharmaceuticals, Inc. operates in the Healthcare sector, Biotechnology industry.
What exchange does AMLX trade on?
AMLX trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,220.51+0.45%
$1.15T cap
Johnson & JohnsonJNJ
$260.86+0.41%
$628.65B cap
AbbVie Inc.ABBV
$248.66-0.57%
$439.33B cap
UnitedHealth Group IncorporatedUNH
$405.59+0.85%
$368.33B cap
Roche Holding AGSWX: ROP
CHF 365.50-0.92%
$357.92B cap
Merck & Co., Inc.MRK
$132.93+1.92%
$328.31B cap
Novartis AGSWX: NOVN
CHF 124.20-1.32%
$290.41B cap
AstraZeneca PLCLON: AZN
£117.02-1.20%
$244.93B cap